PlainPharmaWatch

CMS Open Payments · Tool

Recordati_rare_diseases_inc. vs Potrero Medical, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Potrero Medical, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 6,915, versus 247 for the other company. Its single largest recorded recipient represents 82.7% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Recordati_rare_diseases_inc.
HHI 247 · top recipient 7.9%
Ranked #1,511 of 1,838 companies by HHI
Potrero Medical, Inc.
HHI 6,915 · top recipient 82.7%
Ranked #232 of 1,838 companies by HHI

Payment Overview

Total Payments
$2.3M
% of Industry
0.0%
Transactions
5,992
Avg per Transaction
$391.33
Recipients
5,392
Avg per Recipient
$434.88
Payment Types
7
Top Payment Type
Honoraria
Total Payments
$2.4M
% of Industry
0.0%
Transactions
77
Avg per Transaction
$30.6K
Recipients
60
Avg per Recipient
$39.3K
Payment Types
2
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Recordati_rare_diseases_inc. vs Potrero Medical, Inc. - total reported payments in CMS Open Payments PY2024

Potrero Medical, Inc.$2.4MRecordati_rare_diseases_inc.$2.3M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Recordati_rare_diseases_inc.

Honoraria $355.0K

49.7%

Consulting Fee $171.8K

24.1%

Food and Beverage $118.9K

16.7%

Travel and Lodging $46.0K

6.4%

Compensation for Services Other Than Consulting $20.3K

2.8%

Education $1.1K

0.2%

Potrero Medical, Inc.

Consulting Fee $31.0K

91.5%

Food and Beverage $2.9K

8.5%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Recordati_rare_diseases_inc.

  1. 1

    ELENA CHRISTOFIDES

    $56,440.04 · 38 txns

  2. 2

    COREY CASPER

    $35,754.80 · 20 txns

  3. 3

    MARIA FLESERIU

    $34,950.35 · 12 txns

  4. 4

    WENYU HUANG

    $32,548.62 · 13 txns

  5. 5

    GORDAN SRKALOVIC

    $31,204.69 · 20 txns

Potrero Medical, Inc.

  1. 1

    VANESSA MOLL

    $28,044.38 · 7 txns

  2. 2

    ABBAS AL-QAMARI

    $3,000.00 · 6 txns

  3. 3

    BASSEM M CHEHAB

    $241.12 · 4 txns

  4. 4

    ALFRED RYAN SCHWAB

    $186.83 · 1 txns

  5. 5

    LAURIE L DOUGHERTY

    $162.60 · 1 txns

Summary Comparison

Metric Recordati_rare_diseases_inc. Potrero Medical, Inc.
Total Payments $2.3M $2.4M
% of Industry Total 0.0% 0.0%
Transaction Count 5,992 77
Avg per Transaction $391.33 $30.6K
Recipient Count 5,392 60
Avg per Recipient $434.88 $39.3K
Payment Type Count 7 2
Top Payment Type Honoraria Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.